Yusuke Nakamura to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Yusuke Nakamura has written about Antineoplastic Agents, Alkylating.
Connection Strength
0.206
-
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
Score: 0.149
-
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004 Mar; 24(3):647-55.
Score: 0.057